Ghana CKD Launch – 2025

The Ghana CKD Launch – 2025 is a clinician-focused CPD programme designed to translate the latest cardio-renal-metabolic (CRM) evidence into routine practice in Ghana. Through expert-led talks and case-based discussions, participants will examine early detection strategies, guideline-directed medical therapy (GDMT), and the practical integration of SGLT2 inhibitors—anchored by the EMPA-KIDNEY data—across both diabetic and non-diabetic CKD. The hybrid format ensures broad access while maintaining a strong emphasis on practical clinical decision-making, referral pathways, and multidisciplinary coordination between specialist and primary care.

SESSION TOPICS

1. Why early intervention is key to save the kidneys: The role of the Primary Care Physician

• • Introduce a patient case highlighting CRM disease burden
  • Local epidemiology data for CKD and the need for optimising care
  • Role of PCPs in early screening, diagnosis, and treatment in CKD

2. Cardio-renal benefits of Empagliflozin in EMPA-KIDNEY: The final piece of the puzzle

• • Present and interpret the EMPA-KIDNEY trial data
  • Position newer therapies within GDMT
  • Understand how current guidelines evolved to reflect accumulated evidence

3. Interactive CRM Cases, Panel Discussion & Q&A

• • Early CKD: “Preserving the kidneys for tomorrow”
  • Kidney protection and why RAAS agents alone are not enough in CKD
  • Redefining kidney outcomes; SGLT2 inhibitors—guidelines and practice

4. Role of PCPs in Early Screening, Diagnosis, and Treatment

• • Treatment considerations for CKD with common co-morbidities
  • Highlights from international guidance (e.g., KDIGO) and their local application

WHY YOU SHOULD ATTEND/PARTICIPATE

Apply evidence immediately: Turn EMPA-KIDNEY and related CRM evidence into practical, step-by-step care plans.

Strengthen early detection: Sharpen case-finding, risk stratification, and monitoring to slow CKD progression.

Align with guidelines: Confidently implement KDIGO-aligned, GDMT-based algorithms for both T2DM and non-T2DM CKD.

Bridge primary–specialist care: Clarify referral thresholds, shared-care protocols, and follow-up pathways.

Address co-morbidities: Optimise therapy in the context of hypertension, diabetes, dyslipidaemia, and heart failure.

Earn accredited CPD: Obtain recognised credits while building practical tools (checklists, order sets, monitoring plans).

PROUDLY SPONSORED BY

This is a virtual event scheduled for Wednesday the 24th of September, 2025 at 15:00 GMT.  

Target Audience: Medical Doctors, Pharmacists

Moderator:  

Date: Wednesday, 24th September, 2025 

Time: 15:00 GMT (3:00 PM Local Time)

Don’t miss out on this exciting opportunity to elevate your skills and make a lasting impact CRM!

PARTICIPANT CONSENT AND DATA PRIVACY NOTICE

By registering for the “Ghana CKD Launch - 2025”, you consent to participate in this training hosted by CES on behalf of Bohringer Inghelhiem (BI). Your registration will provide us with the necessary information to facilitate the event and issue CPD accreditation through the Medical and Dental Council (MDC), and the Pharmacy Council. Please note that CES is committed to safeguarding your personal information and will not share any personal data with Roche. Your data will only be shared with the relevant regulatory bodies, such as MDC, for the sole purpose of accrediting you with CPD points earned through this training. Additionally, participants are free to opt out of the meeting at any time, and should you wish to do so, no further action is required on your part. We respect your privacy and ensure that your participation will be treated with the highest level of confidentiality.